Celyad (Formally Known as Cardio3 BioSciences)

112 articles with Celyad (Formally Known as Cardio3 BioSciences)

• 

  BioSpace Global Roundup, Sept. 12

  9/12/2019

  Companies and organizations from across Europe, Asia and North America share updates on their business and pipelines.

• Be The Match BioTherapies® and Celyad Announce Collaboration to Advance Development of Allogeneic CAR-T Therapies

  9/10/2019

  Alliance will support the clinical progression of Celyad’s non-gene edited allogeneic CAR-T candidates

• 

  Clinical Catch-Up: September 2-8

  9/9/2019

  Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
• 

  BioSpace Movers and Shakers: April 5

  4/5/2019

  Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
• 

  BioSpace Movers and Shakers: March 15

  3/15/2019

  Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more.

• Celyad Announces Third Quarter 2017 Business Update

  11/17/2017

  The Company ended the quarter with €40 million in cash.

• Celyad Reports A First Complete Response In A Relapsed Refractory AML Patient In The THINK Trial

  10/3/2017

• Celyad Reports First Half 2017 Financial Results And Operational Progress

  8/29/2017

• Celyad Announces New Agreements With Celdara Medical And Dartmouth College

  8/4/2017

• BioLife Solutions, Inc. Executes Supply Agreement With Celyad For CryoStor Use In Natural Killer Receptor Based T-Cell (NKR-T) Platform Targeting Solid Tumors And Blood Cancers

  7/31/2017

• Celyad Announces Initiation Of The SHRINK Trial

  7/20/2017

• Celyad Publishes Additional Pre-Clinical Data In Support Of THINK Trial

  6/21/2017

• Celyad Reports Promising Early Results At First Dose Level Of The Solid Arm Of The THINK Trial

  6/19/2017

• Celyad Obtains Additional US Patent For Cancer Treatment Based On TCR-Deficient Allogeneic CAR-T Cells

  5/30/2017

• Celyad Announces First Quarter 2017 Business Update

  5/19/2017

• Celyad Announces First Quarter 2017 Business Update

  5/19/2017

• FDA Grants Fast Track Designation For Celyad’s Ischemic Heart Failure Therapy, C-Cure

  5/11/2017

• Celyad Grants To Novartis AG A Non-Exclusive License For Its Allogeneic TCR-Deficient CAR-T Cells Patents

  5/2/2017

• Celyad Reports 2016 Financial And Operating Results And Expected Key Milestones For 2017

  3/23/2017

• USPTO Rejects New Reexamination Request Against Celyad’s US Patent For Production Of Allogeneic TCR-Deficient CAR-T Cells

  3/16/2017